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Abstract
Background: Stereotactic body radiotherapy (SBRT) may yield disease control for prostate cancer in a brief,
hypofractionated treatment regimen without increasing treatment toxicity. Our report presents a 6-year update
from 304 low- (n = 211), intermediate- (n = 81), and high-risk (n = 12) prostate cancer patients who received
CyberKnife SBRT.
Methods: The median PSA at presentation was 5.8 ng/ml. Fifty-seven patients received neoadjuvant hormonal
therapy for up to one year. The first 50 patients received a total dose of 35 Gy in 5 fractions of 7 Gy. The
subsequent 254 patients received a total dose of 36.25 Gy in 5 fractions of 7.25 Gy. Toxicity was assessed with the
Expanded Prostate Cancer Index Composite questionnaire and the Radiation Therapy Oncology Group urinary and
rectal toxicity scale. Biochemical failure was assessed using the nadir + 2 definition.
Results: No patients experienced Grade III or IV acute complications. Fewer than 5% of patients experienced any
acute Grade II urinary or rectal toxicities. Late urinary Grade II complications were observed in 4% of patients
treated to 35 Gy and 9% of patients treated to 36.25 Gy. Five (2%) late Grade III urinary toxicities occurred in
patients who were treated with 36.25 Gy. Late Grade II rectal complications were observed in 2% of patients treated
to 35 Gy and 5% of patients treated to 36.25 Gy. Bowel and urinary quality of life (QOL) scores initially decreased,
but later returned to baseline values. An overall decrease of 20% in the sexual QOL score was observed. QOL in
each domain was not differentially affected by dose. For patients that were potent prior to treatment, 75% stated
that they remained sexually potent. Actuarial 5-year biochemical recurrence-free survival was 97% for low-risk, 90.7%
for intermediate-risk, and 74.1% for high-risk patients. PSA fell to a median of 0.12 ng/ml at 5 years; dose did not
influence median PSA levels.
Conclusions: In this large series with long-term follow-up, we found excellent biochemical control rates and low
and acceptable toxicity, outcomes consistent with those reported for from high dose rate brachytherapy (HDR BT).
Provided that measures are taken to account for prostate motion, SBRT’s distinct advantages over HDR BT include
its noninvasiveness and delivery to patients without anesthesia or hospitalization.
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Introduction
Conventional treatments for localized prostate cancer
target local control at the potential expense of morbidity
and decreased quality of life. Urinary function impair-
ment occurs in 5-28% of patients at 2 years after radical
prostatectomy (RP) and in 2-14% of patients at 2 years
after external-beam radiation therapy (EBRT) [1,2].
Bowel distress is found in 3-21% of RP patients and
8-37% of EBRT patients 2 years after treatment [1].
Erectile dysfunction has been reported in 51-82% and
30-51% of patients 2 years after RP and EBRT, respect-
ively [1,3,4]. Sexual quality-of-life (QOL) estimates show
similar results for these treatments [2], although it
should be noted that the radiotherapy patients in this
study were older on average, and therefore more likely
to have lower sexual QOL. Indeed, the rate of such
complications and the extent to which they reduce the
QOL of prostate cancer patients contributed to a recent
recommendation from the United States Preventive
Services Task Force (USPTF) against routine prostate-
specific antigen (PSA) screening for prostate cancer in
men age 75 or older [5]. Furthermore, the rate of com-
plications and decreased QOL has prompted researchers
to consider using stereotactic body radiotherapy (SBRT)
(i.e., highly targeted radiotherapy with large daily doses
of radiation) to try to increase disease control while
decreasing side effects.
Radiobiologically, slowly proliferating prostate cancer
cells are thought to have a low α/β ratio; in two recent
reviews of studies in which the fractional dose was
varied, the α/β ratio continued to average about 1.5 Gy
[6,7], consistent with the earliest estimates of Brenner
and Hall [8]. This low α/β ratio suggests that prostate
cancer cells have a high sensitivity to dose per fraction.
This sensitivity suggests that a hypofractionated radiation
delivery regime with a large radiation dose delivered in a
smaller number of fractions may be advantageous.
The first reported hypofractionated radiation therapy
treatments for prostate cancer occurred in the early
1960s [9]. Treatments of 36 Gy delivered in 6 equal frac-
tions were motivated by resource limitations rather than
radiobiology. Nevertheless, two decades of follow-up has
confirmed that this regimen leads to favorable and long-
term local response, survival, and safety. Subsequently,
hypofractionated prostate cancer treatment has been
performed with EBRT in per-fraction doses of 2.5-3.1 Gy
[10-13], with brachytherapy (BT) in per-fraction doses of
5.5-11.5 Gy [14-16], and with linac-based SBRT in per-
fraction doses of 6.7 Gy in 5 fractions [17]. In the first
paper to report on CyberKnife® SBRT (Accuray Incorpo-
rated, Sunnyvale, CA), King et al. reported a median 33-
month follow-up for patients that received 5 fractions of
7.25 Gy (for a total dose of 36.25 Gy). They did not
observe any biochemical failure and the early and late
toxicity profiles of their patients were no worse than
equivalent historical cohorts treated with conventional
EBRT [18]. We found similar results in an earlier paper
that discussed 304 patients who were treated with
CyberKnife and had a limited median follow-up of
19 months [19]. At 19 months, toxicity was low and
early PSA control was encouraging. Other reports have
since been published that found similarly low toxicity
and high efficacy [20-24]. In a study of 41 low-risk
patients with the longest follow-up from the combined
Stanford and Naples, Florida groups, Freeman and King
[25] reported a 5-year biochemical disease-free survival
rate of 93% that was accompanied by low toxicity. Thus,
although long-term follow-up is limited, hypofrac-
tionated treatment of prostate cancer can result in
effective biochemical control while maintaining low
rectal and bladder toxicities.
Our report presents a 6-year update of treatment
results from 304 low-, intermediate-, and high-risk pros-
tate cancer patients who received CyberKnife SBRT.
Particular attention is given to biochemical control and
urinary, rectal, and sexual toxicities.
Methods and materials
Patient population
Data were analyzed for all clinically localized prostate
cancer patients who were treated with CyberKnife SBRT
at Winthrop University between April 2006 and July
2008. The treatment protocol was IRB-approved and the
first 15 patients were treated in a prospective fashion to
assess the feasibility of the approach in our hands.
Subsequent patients were treated according to this
approved protocol, but not as part of a prospective
study. All patients provided informed consent for their
outcomes to be incorporated in this retrospective study.
All 304 patients had adenocarcinoma of the prostate. Of
these patients, 280 (92.2%) of them presented with
clinical stage T1c N0 M0 and 24 (7.8%) presented with
clinical stage T2a N0 M0 (as determined by a physical
exam and bone and CT scans). The median PSA at pres-
entation was 5.8 ng/ml (range, 0.7-27.3 ng/ml). Table 1
details the patient characteristics. All patients signed
consent statements and were informed of the potential
risks involved with CyberKnife treatment. The treatment
protocol received institutional review board approval.
Hormone therapy
Fifty-seven patients received neoadjuvant hormonal
therapy. As this therapy was usually stopped at the time
of consultation, 29 (51%) of those patients received it for
up to three months. The remaining 28 patients (49%)
received hormone therapy for up to one year at the
discretion of the patient’s urologist.
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Treatment planning and delivery
Image-guided SBRT was delivered to all patients using
the CyberKnife with Multiplan® inverse treatment plan-
ning and motion tracking throughout treatment based
on internal fiducials. A detailed description of the
CyberKnife system can be found elsewhere [26].
Approximately 2 weeks before treatment planning, 4
gold fiducial seeds were placed transperineally in each
patient to allow for motion tracking during treatment.
Two of the seeds were implanted at the prostate apex
and two were implanted at its base. After allowing time
for possible seed migration, treatment planning was
performed prior to the treatment day using a CT scan
(1.5-mm cuts) with MRI fusion. All pretreatment
imaging was performed with the patient in the same
position that was used for his treatment delivery. For
low-risk patients, just the prostate made up the gross
target volume (GTV). For intermediate- to high-risk
patients who had a Gleason Score of greater than 6 and
a PSA of greater than 15 ng/ml, the proximal half of the
seminal vesicles was added to the GTV. After the GTV
was delineated, a margin was added to create the plan-
ning target volume (PTV). For low- and intermediate-
risk patients, the margin was extended 5 mm on all sides
except for posteriorly (by the rectum) where a 3-mm
margin was used. For high-risk patients, an 8-mm
margin was added to the involved side. All patients had
the bladder, prostate, rectum, seminal vesicles, and
penile bulb contoured; the urethra was not identified.
SBRT was delivered at two dose levels. The first 50
patients (16%) received a total dose of 35 Gy in 5
fractions of 7 Gy each to cover at least 96% of the PTV.
The subsequent 254 patients (84%) received a total dose
of 36.25 Gy in 5 fractions of 7.25 Gy to cover at least
96% of the PTV. The dose was increased to 7.25 Gy per
fraction when preliminary reports at scientific meetings
indicated that the higher dose could be delivered safely
(based on early results of the study by King et al. of
Stanford University; [18]). The mean number of beams
was 152 (range, 140–170). The mean D50 to the bladder
and rectum was 43% and 41% of the prescribed dose,
respectively.
Treatments were performed on five consecutive days.
In the morning before each treatment, patients com-
pleted a bowel prep that included Dulcolax® (Boehringer
Ingelheim, Ingelheim, Germany) and a Fleet enema (C.B.
Fleet Company, Inc., Lynchburg, Virginia). In addition,
at least 15–20 minutes before treatment all patients
received 1500 mg of amifostine (MedImmune, LLC,
Gaithersburg, MD) that was mixed in saline and instilled
into the rectum.
Follow-up schedule and toxicity assessment
Each patient was seen for follow-up three weeks after
his final treatment, four months after that, and every six
months thereafter. After two years, follow-up was done
annually. Toxicity was assessed at every follow-up visit
and used the Expanded Prostate Cancer Index Composite
(EPIC) questionnaire [27] and the Radiation Therapy
Oncology Group (RTOG) urinary and rectal toxicity scale.
Table 1 Patient characteristics at diagnosis
Age at diagnosis Years
Mean (range) 69.2 (45 – 88)
Age at diagnosis Number of
Patients
Percent of
Patients
45–49 1 0.3
50–54 7 2.3
55–59 23 7.6
60–64 35 11.5
65–70 54 17.8
70–74 80 26.3
75–79 54 17.8
80–84 36 11.8
85-88 14 4.6
PSA level at diagnosis ng/mL
Mean (range) 6.08 (0.7 to 27.7)
Median 5.8
PSA level at diagnosis Number of
Patients
Percent of
Patients
<4 ng/mL 59 19.4
4–10 ng/mL 203 66.8
>10–20 ng/mL 40 13.2
>20 ng/mL 2 0.7
Clinical Stage Number of
Patients
Percent of
Patients
T1cN0M0 280 92.1
T2aN0M0 24 7.9
Gleason Score Number of
Patients
Percent of
Patients
= 6 222 73
=7 70 23
> 8 12 4
Hormone Treatment Number of
Patients
Percent of
Patients
No 247 81.3
Yes 57 18.8
Risk Assessment: Criteria Number of
Patients
Percent of
Patients
Low Risk: Gleason Score≤ 6 and
PSA≤ 10 ng/ml.
211 69.4
Intermediate Risk: Gleason = 7 or
PSA > 10 and PSA < 20
81 26.6
High Risk: Gleason≥ 8 or PSA > 20 12 0.7
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Acute toxicity was defined as those events that presented
and resolved within the first 3 months following
treatment. PSA was assessed by the referring urologist 3
and 6 months after treatment and every 6 months
thereafter. Biochemical failure was the end point of the
study and used the Phoenix (nadir + 2) biochemical failure
definition [28].
Results
Follow-up
The median follow-up for all patients was 60 months
(range, 8–78 months). Patients who received the higher
dose (36.25 Gy) had a median follow-up of 60 months
(range, 8–72 months). For the lower dose (35 Gy), the
median follow-up was 72 months (range, 9–78 months).
Sixteen patients were lost to follow-up. Although there
were 5 deaths in the 35 Gy group and 21 deaths in the
36.25 Gy group, none of these deaths were due to pros-
tate cancer.
Acute toxicity
Except for one patient who died from causes other than
prostate cancer at 4 months, all patients received a
toxicity follow-up at 3 weeks and 5 months. Acute tox-
icity profiles were thus collected for 303 patients. Table 2
presents the RTOG-scale-graded acute urinary and rec-
tal toxicities that were observed during the first 3 months
as a function of treatment dose. No patients experienced
any Grade III or IV acute complications. Fewer than 5%
of patients (14/303) experienced any acute Grade II
urinary or rectal toxicities.
Late toxicity
Figure 1 presents late urinary and rectal toxicities and
differentiates them for all patients by dose. Late urinary
Grade II complications were observed in 4% of patients
treated to 35 Gy and 9% of patients treated to 36.25 Gy.
Five (2%) late Grade III urinary toxicities occurred in
patients who were treated with 36.25 Gy. Although a
difference in late urinary complication rates was
observed between patients who received 35 Gy or
36.25 Gy, this observation was not statistically significant
(p > 0.5). Late rectal Grade II complications were
observed in 2% of patients treated to 35 Gy and 5% of
patients treated to 36.25 Gy. Late rectal complications
also did not differ between groups (p > 0.5).
Quality of life
All patients completed the initial EPIC questionnaire
prior to treatment. For subsequent time points, the
number of patients that completed this questionnaire
varied, depending on how many patients reached each
follow-up time point and also completed the question-
naire. Figure 2 shows the EPIC scores for bowel, urinary,
and sexual QOL. Bowel and urinary QOL scores initially
decreased, but then returned to baseline values. For
sexual QOL, an overall gradual decrease of about 10% in
the QOL score was observed. QOL in each domain was
not differentially affected by dose (see Figure 3). To
further examine sexual QOL and determine if patients
remained potent, we verbally screened patients that were
potent prior to treatment (n = 228). At a median
60 months follow-up (range, 48–78 months), 75%
percent of them (172/228) stated that they remained
sexually potent; 25% of these patients required medica-
tion. EPIC QOL scores are presented as a function of
dose in Figure 3. In no case was dose a significant deter-
minant of QOL (p < 0.05).
Biochemical control and PSA
Actuarial 5-year biochemical recurrence-free survival
was 97% for low-risk, 90.7% for intermediate-risk, and
74.1% for high-risk patients (Figure 4). For low-risk
patients, there was no difference in biochemical disease-
Table 2 Acute bladder/rectal toxicity using RTOG scoring after prostate treatment using the 35 and 36.25 Gy doses
RTOG grade% (number) of patients
Total dose 0 I II III & IV
Acute urinary 35 Gy 24% (12) 72% (36) 4% (2) –
36.25 Gy 20.5% (52) 74.8% (190) 4.7% (12) –
Acute rectal 35.00 Gy 20% (10) 76% (38) 4% (2) –
36.25 Gy 22.% (56) 74.4% (189) 3.5% (9) –
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Figure 1 RTOG-graded late toxicity for patients treated with 35
or 36.25 Gy.
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free survival (BDFS) as a function of dose, ie 35 Gy vs
36.25 Gy (98% vs 97%). In fact, 43 low-risk and 7
intermediate-risk patients that were treated with 35 Gy
had a BDFS of 98% at 6 years. In the intermediate-risk
category, patients with a Gleason score of 4 + 3 had a 5-
year BDFS of 84% vs a bRFS of 95% for those with a
Gleason score of less than 4 + 3. PSA fell to a median of
0.12 ng/ml at 5 years; dose did not influence median
PSA levels (see Figure 5). PSA for hormone-treated
patients versus those not treated with hormones is also
shown in Figure 5. PSA was clearly lower at the 3-
month time point for hormone-treated patients, but not
at other time points. A PSA bounce of greater than
0.2 ng/ml occurred in 51/304 (17%) of patients with a
median time-to-bounce of 30 months. The median
bounce was 0.55 ng/ml.
Discussion
In this large series with long-term follow-up, we found
excellent biochemical control rates and low and accept-
able toxicity. PSA fell steadily after treatment and
achieved very low levels (mean of 0.25 ng/ml) within 4–
5 years, findings that portend good long-term disease
control outcomes [29,30]. These findings support an
estimate of the α/β ratio of 1.5 Gy. A ratio of 1.5 Gy
means that we have delivered an equivalent dose (EQD)
of 90–96 Gy at 1.8 Gy per fraction, an EQD which
accounts for the higher control rates than those seen
with the use of 81 Gy [29]. Although our results with
high-risk patients are encouraging, it is important to
note that our study included only 12 patients and more
data is necessary to confirm these findings.
Our outcomes are consistent with those that have
resulted from high dose rate brachytherapy (HDR BT),
with or without EBRT [15,16]. In a recent paper Demanes
et al. [14] reported an 8-year recurrence-free survival of
97% in a mixed cohort of low and intermediate-risk
patients. If additional follow-up confirms that this level of
long-term disease control can be obtained with SBRT,
SBRT’s advantages over HDR BT, primarily its non-
invasiveness and ability to deliver treatment to patients
without anesthesia or hospitalization may make it the
preferred modality.
We employed two dose levels in our study. We
initially treated patients with 35 Gy but escalated to
36.25 Gy six months into the study after observing low
acute toxicity at 35 Gy and after reports from others of
acceptable toxicity at a dose of 36.25 Gy. Based on
current data, however, the higher dose does not appear
to be necessary for low and low-intermediate patients.
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Figure 2 Mean EPIC quality of life scores. Under the figure are
percentages of patients reaching each time point that completed
the EPIC ((number completing EPIC / number at risk) X 100).
EPIC QUALITY of LIFE
0 12 24 36 48 60
0
50
100
35 Gy
36.25 Gy
Sexual
Months
EP
IC
 S
co
re
 (%
 ba
se
lin
e)
0 12 24 36 48 60
0
20
40
60
80
100
35 Gy
36.25 Gy
Bowel
Months
EP
IC
 S
co
re
 (%
 ba
se
lin
e)
0 12 24 36 48 60
0
50
100
35 Gy
36.25 Gy
Urinary
Months
EP
IC
 S
co
re
 (%
 ba
se
lin
e)
Figure 3 Mean EPIC quality of life scores as a function of dose. All differences were not significant (p > 0.05).
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No difference in PSA control or nadirs were seen
between the two doses, a finding which corroborated a
recent matched-pairs study with 48 month follow-up
[31]. A trend to increased toxicity with the 36.25 Gy
dose was observed. It is possible that these events did
not rise to the level of statistical significance due to the
small number of patients within the 35 Gy group. Due
to these findings, we resumed treating low- and low-
intermediate risk patients with 35 Gy soon after the
present study was completed. With more patients and
longer follow-up a significant improvement in toxicity at
the lower dose may be observed, in which case 35 Gy
may be the optimal dose to assure long-term disease
control and low toxicity. Such a finding would imply a
flattening of the biologically equivalent dose response
curve from 90–96 Gy EQD (assuming an α/β ratio of
1.5 Gy).
Our results are supported by a recent study of 1101
patients in a pooled analysis from eight institutions [32],
reported at the 2012 meeting of the American Society of
Radiation Oncology (ASTRO). This analysis reported
only on biochemical control outcomes and found 96%,
92%, and 80% control with five-year actuarial follow-up
for low-, intermediate- and high-risk patients, respect-
ively. These results excluded the PSA failures that
subsequently resolved on their own (i.e., “bounces”).
Importantly, the three-year median follow-up results
were excellent (at 80% control) for more than 100
patients with high-risk disease. These outcomes approxi-
mate those obtained in the current study, as well as from
a study by Katz et al. [33] that reported long-term
follow-up results for high-risk patients that received a
CyberKnife boost after EBRT. In this study a biochem-
ical control rate of 77.7% at 3 years was obtained for
high-risk patients who received 45 Gy to the pelvis
followed by a CyberKnife boost of 18–21 Gy. No differ-
ences were found between patients who received 35 Gy
or doses as high as 40 Gy. The use of ADT also did not
affect outcomes. Longer follow-up with more patients is
warranted before firm conclusions can be made about
the efficacy of SBRT monotherapy or SBRT as a boost
for these patients at a higher risk for disease outside the
prostate.
Because surgery is often used instead of radiation to
treat prostate cancer, patients need information on both
disease control and QOL changes associated with either
modality. To better gauge the impact of prostate cancer
treatment on QOL, one study compared the QOL
responses from a large group of patients who had
recently received CyberKnife SBRT to those of a similar
group who instead underwent open surgery [34]. EPIC
scores were used to assess QOL. For all time intervals
up to 36 months, the patients who received SBRT had
superior EPIC scores (in terms of urinary and sexual do-
mains) than those who underwent surgery. Bowel
domain was slightly worse in the short term for those in
the SBRT group, but patients in both the SBRT and
surgery groups had excellent preservation of bowel func-
tion after 12 months. It is important to note that surgical
patients underwent open prostatectomy. It is possible
that improvements in prostatectomies, including the use
of laparoscopic techniques, will improve QOL post-
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surgery. On the other hand, SBRT patients in this study
were older, on average, a factor that could have swayed
QOL in favor of surgery. Although it is clearly not
appropriate to assert forcefully the superiority of SBRT
over surgery based on the data in this study, there is at
least no evidence that SBRT results in poorer QOL
outcomes for prostate cancer patients.
Conclusions
In this study of 304 patients followed out to 6 years, we
found excellent biochemical control rates with low and
acceptable toxicity. Provided prostate motion is tracked
and accounted for, high-dose, hypofractionated SBRT for
prostate cancer appears that it may be an attractive treat-
ment option for patients with low- and intermediate-risk
disease. Longer-term follow-up with additional patients is
needed to firmly assess efficacy and toxicity of SBRT
relative to other, more established approaches, and its
utility in high-risk patients.
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